Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H18N2O3 |
Molecular Weight | 226.2722 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
InChI
InChIKey=VIROVYVQCGLCII-UHFFFAOYSA-N
InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
Molecular Formula | C11H18N2O3 |
Molecular Weight | 226.2722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/ppa/amobarbital-sodium.html
Sources: https://www.drugs.com/ppa/amobarbital-sodium.html
AMOBARBITAL is a barbiturate derivative with hypnotic and sedative properties. In an in vitro study in rat thalamic slices amobarbital worked by activating GABAA receptors, which decreased input resistance, depressed burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increased both the amplitude and decay time of inhibitory postsynaptic currents. Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6099281 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Amytal Sodium Approved UseUnknown |
|||
Primary | Amytal Sodium Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Seven cases of somnambulism induced by drugs. | 1979 Jul |
|
The central nervous effects of Mitragyna africanus (Willd) stembark extract in rats. | 2001 Oct |
|
Mitochondrial respiratory chain as a new target for anti-ischemic molecules. | 2002 Apr 19 |
|
Transcortical mixed aphasia due to cerebral infarction in left inferior frontal lobe and temporo-parietal lobe. | 2002 Feb |
|
Effect of the new matrix metalloproteinase inhibitor RO-28-2653 on mitochondrial function. | 2002 Feb 15 |
|
Wada testing reveals frontal lateralization for the memorization of words and faces. | 2002 Jan 1 |
|
Amobarbital inhibits K(+)-stimulated glucose oxidation in cerebellar granule neurons by two mechanisms. | 2002 Jun 20 |
|
Key structural features of ligands for activation of human pregnane X receptor. | 2004 Apr |
|
Neurophysiologic monitoring and pharmacologic provocative testing for embolization of spinal cord arteriovenous malformations. | 2004 Aug |
|
Endovascular management of dolichoectasia of the posterior cerebral artery report. | 2004 Nov-Dec |
|
Selective GABA-receptor actions of amobarbital on thalamic neurons. | 2004 Oct |
|
Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy in high myopia: a prospective clinical study. | 2004 Sep 14 |
|
[Rotenone-insensitive NADH oxydation in mitochondrial suspension occurs by NADH dehydrogenase of respiratory chain fragments]. | 2004 Sep-Oct |
|
Role of endothelial mitochondria in oxidant production and modulation of neutrophil adherence. | 2004 Sep-Oct |
|
Amytal interview using intravenous lorazepam in a patient with dissociative fugue. | 2006 Nov-Dec |
|
Different states of energy metabolism in the vertebrate retina can be identified by stimulus-related changes in near UV transmission. | 2007 Apr |
|
Comorbid substance-use in schizophrenia: the file drawer effect, In reply to: Talamo et al., 2006. "Comorbid substance-use in schizophrenia: relation to positive and negative symptoms". | 2007 Feb |
|
Seizures during intracarotid methohexital and amobarbital testing. | 2007 Feb |
|
In silico prediction of pregnane X receptor activators by machine learning approaches. | 2007 Jan |
|
[Applications of optical topography in neurosurgery]. | 2007 May |
|
Perioperative modulating factors on astigmatism in sutured cataract surgery. | 2009 Dec |
|
Acquired and congenital disorders of sung performance: A review. | 2009 Nov 12 |
|
Multiple myeloma presenting as CEA-producing rectal cancer. | 2010 Mar 31 |
|
Identification of a novel phosphorylation site in hepatitis C virus NS5A. | 2010 Oct |
Patents
Sample Use Guides
Sedative: 30 to 50 mg given 2 or 3 times daily.
Hypnotic: 65 to 200 mg at bedtime.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6099281
To 100mkl of the tissue homogenate were added 50 mkl of [3SS]TBPS (at the appropriate concentration, and made in 1 M NaBr), 50 mkl of 50 mM Tris Citrate buffer (to define total binding) or AMOBARBITAL at 100mkM or 50mkl of 40mkM picrotoxinin (to define nonspecific binding). The mixture was incubated 90 min at 21°C and then filtered over glass-fiber filters (Schleicher and Schuell No. 32). Filters were washed three times with 5 ml 0.9% (w:v) NaC1 equilibrated to 21°C and then counted by liquid scintillation spectrometry.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:04 GMT 2023
by
admin
on
Fri Dec 15 15:01:04 GMT 2023
|
Record UNII |
GWH6IJ239E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN05CA02
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
||
|
NCI_THESAURUS |
C67084
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
||
|
WHO-ATC |
N05CA02
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
||
|
DEA NO. |
2125
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
||
|
LIVERTOX |
46
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GWH6IJ239E
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
719
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | RxNorm | ||
|
D000654
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
DB01351
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
200-330-7
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
184
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
GWH6IJ239E
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
1111
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
57-43-2
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
100000087425
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
2164
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
2673
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
DTXSID9020081
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
3286
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
SUB05468MIG
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
1030001
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
AMOBARBITAL
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL267894
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
10815
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | |||
|
m1837
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
C76523
Created by
admin on Fri Dec 15 15:01:04 GMT 2023 , Edited by admin on Fri Dec 15 15:01:04 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||